IGLV3-21: A Potential Drug Target and Biomarker (G28796)

Target Name: IGLV3-21

NCBI ID: G28796

IGLV3-21

Other Name(s): IGLV321 | V2-14 | immunoglobulin lambda variable 3-21 | Immunoglobulin lambda variable 3-21

IGLV3-21: A Potential Drug Target and Biomarker

IGLV3-21 is a protein that is expressed in various tissues of the human body. Its full name is Integrin-like variable subunit 3 (IGLV3), and it is a member of the integrin family. This protein plays a crucial role in cell-cell adhesion, migration, and invasion. IGLV3 has also been shown to be involved in the development and progression of various diseases, including cancer. As a result, IGLV3 has emerged as a promising drug target and biomarker.

Disease-Related Function

IGLV3 has been shown to be involved in the development and progression of various diseases, including cancer. For example, studies have shown that IGLV3 is overexpressed in various types of cancer, including breast, ovarian, and prostate cancer. This overexpression is associated with poor prognosis and increased cancer-related mortality. Additionally, IGLV3 has been shown to promote the growth and survival of cancer cells in various models, including cell culture and animal models.

In addition to its role in cancer development, IGLV3 has also been linked to several other diseases and conditions. For example, IGLV3 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. Additionally, IGLV3 has been linked to skin diseases, such as psoriasis and dermatitis.

As a Drug Target

IGLV3 has been shown to be a potential drug target due to its involvement in several diseases and conditions. Its overexpression in various diseases, including cancer, makes it an attractive target for small molecules or biochemicals that can inhibit its activity. Additionally, IGLV3's role in cell-cell adhesion and migration makes it a potential target for drugs that can modulate these processes.

One approach to targeting IGLV3 is to use small molecules that can inhibit its activity in cell-cell adhesion and migration. These small molecules can be found through various screening methods, including high-throughput screening and screening assays. For example, researchers have shown that inhibitors of the protein FAK, which is similar to IGLV3, can be effective in modulating the activity of IGLV3 in cell-cell adhesion and migration.

As a Biomarker

IGLV3 has also been shown to be a potential biomarker for several diseases, including cancer. Its overexpression in various diseases makes it an attractive target for diagnostic tools that can detect its expression. For example, researchers have shown that IGLV3 can be used as a biomarker for breast cancer, using techniques such as qRT-PCR and western blotting.

In addition to its potential as a drug target, IGLV3 has also been shown to be a potential biomarker for several other diseases, including neurodegenerative diseases and skin diseases. For example, IGLV3 has been shown to be involved in the development of Alzheimer's disease, using techniques such as RNA interference and protein expression. Additionally, IGLV3 has been linked to skin diseases, such as psoriasis and dermatitis, and has been shown to be involved in these conditions using techniques such as gene editing and cell-based assays.

Conclusion

IGLV3 has emerged as a promising drug target and biomarker due to its involvement in several diseases and conditions. Its overexpression in various diseases, including cancer, makes it an attractive target for small molecules or biochemicals that can inhibit its activity. Additionally, IGLV3 has also been shown to be involved in the development and progression of

Protein Name: Immunoglobulin Lambda Variable 3-21

Functions: V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268)

The "IGLV3-21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLV3-21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets